Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Double-Blind, Randomized, Placebo-Controlled Dose Finding Study of the Efficacy and Safety of 2 Target Doses of Org 34517 Used as Adjunctive Therapy in Subjects With Psychotic Major Depression (Major Depressive Episode, Severe, With Psychotic Features).

Next Previous
X
Search
Trial Profile

Prospective, Double-Blind, Randomized, Placebo-Controlled Dose Finding Study of the Efficacy and Safety of 2 Target Doses of Org 34517 Used as Adjunctive Therapy in Subjects With Psychotic Major Depression (Major Depressive Episode, Severe, With Psychotic Features).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PT 150 (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms Hermes
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 30 Sep 2013 Added Lead centre Merck as reported by ClinicalTrials.gov record (NCT00212797).
    • 30 Sep 2013 Added Lead centre Merck as reported by ClinicalTrials.gov record (NCT00212797).
    • 06 Oct 2009 Actual end date changed from (1 Nov 2005) to (1 Jul 2006) as reported by ClinicalTrials.gov. record (NCT00212797).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top